Preclinical data from lung adeno- and squamous cell carcinoma furthermore indicate that BCL-2 inhibitors such as APG-2575 were capable of reprogramming macrophages to a tumor suppressing M1 phenotype, thereby promoting the response to anti-PD-1 therapy [103]. Here, BCL2 is linked to neoplasm.